Tags

Type your tag names separated by a space and hit enter

Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.
Sleep Med. 2008 Dec; 9(8):899-902.SM

Abstract

OBJECTIVE

To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms.

METHODS

Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored.

RESULTS

The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r=-0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r=-0.04). The age-at-onset by treatment interaction was non-significant (P=0.952 for the IRLS and P=0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect.

CONCLUSIONS

These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.

Links

  • Publisher Full Text
    • Aggregator Full Text

    Authors+Show Affiliations

    Allen RP
    Johns Hopkins Bayview Medical Center, Neurology and Sleep Medicine, Baltimore, MD 21224, USA. RichardJHU@mac.com
    Ritchie SY
    No affiliation info available

    MeSH

    AdolescentAdultAge FactorsAge of OnsetAgedChildChild, PreschoolDopamine AgonistsDouble-Blind MethodFemaleHumansIndolesMaleMiddle AgedRestless Legs SyndromeSeverity of Illness IndexTreatment OutcomeYoung Adult

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    18024167

    Citation

    Allen, Richard P., and Sally Y. Ritchie. "Clinical Efficacy of Ropinirole for Restless Legs Syndrome Is Not Affected By Age at Symptom Onset." Sleep Medicine, vol. 9, no. 8, 2008, pp. 899-902.
    Allen RP, Ritchie SY. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Med. 2008;9(8):899-902.
    Allen, R. P., & Ritchie, S. Y. (2008). Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Medicine, 9(8), 899-902.
    Allen RP, Ritchie SY. Clinical Efficacy of Ropinirole for Restless Legs Syndrome Is Not Affected By Age at Symptom Onset. Sleep Med. 2008;9(8):899-902. PubMed PMID: 18024167.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. AU - Allen,Richard P, AU - Ritchie,Sally Y, Y1 - 2007/11/19/ PY - 2007/05/24/received PY - 2007/08/20/revised PY - 2007/08/22/accepted PY - 2007/11/21/pubmed PY - 2009/2/20/medline PY - 2007/11/21/entrez SP - 899 EP - 902 JF - Sleep medicine JO - Sleep Med. VL - 9 IS - 8 N2 - OBJECTIVE: To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms. METHODS: Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored. RESULTS: The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r=-0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r=-0.04). The age-at-onset by treatment interaction was non-significant (P=0.952 for the IRLS and P=0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect. CONCLUSIONS: These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset. SN - 1389-9457 UR - https://www.unboundmedicine.com/medline/citation/18024167/Clinical_efficacy_of_ropinirole_for_restless_legs_syndrome_is_not_affected_by_age_at_symptom_onset_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1389-9457(07)00320-6 DB - PRIME DP - Unbound Medicine ER -